Skip to main content

Advertisement

SpringerLink
Log in

Treatment of myopic choroidal neovascularization with posterior sub-Tenon’s bevacizumab injection (Avastin®)

  • Case Report
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The aim of this study was to report the successful treatment of choroidal neovascularization (CNV) in pathologic myopia (PM) with a posterior sub-Tenon bevacizumab (PSTB; Avastin®) injection. The study was a prospective case series including nine eyes of eight patients with PM and CNV. All nine eyes were injected with PSTB (12.5 mg/0.5 ml). Treatment effectiveness was evaluated with optical coherence tomography (OCT). If intraretinal edema or subretinal fluid were detected, injections were repeated after 2 weeks. The main outcome measures were logMAR best-corrected visual acuity (BCVA) and central foveal thickness. The mean follow-up time was 77.56 weeks. BCVA improved by a mean of −0.38 logMAR (>3 lines). The average reduction in absolute central foveal thickness was 25.67 μm. OCT revealed marked CNV volume reduction and fluid-free status in seven eyes. The fluid-free status remained for ≥1 year in these eyes. Fluorescein angiography revealed CNV resolution in three eyes. Corneal stromal penetration of subconjunctival bevacizumab has been demonstrated in animal studies. PSTB may be an equally effective, yet less invasive alternative for the treatment of myopic CNV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Sperduto RD et al (1983) Prevalence of myopia in the United States. Arch Ophthalmol 101(3):405–407

    Article  CAS  PubMed  Google Scholar 

  2. Tano Y (2002) Pathologic myopia: where are we now? Am J Ophthalmol 134(5):645–660

    Article  PubMed  Google Scholar 

  3. Tokoro T (1988) On the definition of pathologic myopia in group studies. Acta Ophthalmol Suppl 185:107–108

    CAS  PubMed  Google Scholar 

  4. Liu JH et al (2001) Visual impairment in a Taiwanese population: prevalence, causes, and socioeconomic factors. Ophthalmic Epidemiol 8(5):339–350

    CAS  PubMed  Google Scholar 

  5. Soubrane G, Coscas G (2006) Choroidal neovascular membrane in degenerative myopia. In: Ryan SJ (ed) Retina. Elsevier Mosby, Philadelphia, PA, pp 1115–1133

    Chapter  Google Scholar 

  6. Grossniklaus HE, Green WR (1992) Pathologic findings in pathologic myopia. Retina 12(2):127–133

    Article  CAS  PubMed  Google Scholar 

  7. Miller DG, Singerman LJ (2001) Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 12(3):222–224

    Article  CAS  PubMed  Google Scholar 

  8. Nguyen QD et al (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89(10):1368–1370

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Chen WL et al (2009) Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50(4):1659–1665

    Article  PubMed  Google Scholar 

  10. McBrien NA, Norton TT (1994) Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew. Exp Eye Res 59(4):475–486

    Article  CAS  PubMed  Google Scholar 

  11. Liu KR, Chen MS, Ko LS (1986) Electron microscopic studies of the scleral collagen fiber in excessively high myopia. Taiwan Yi Xue Hui Za Zhi 85(11):1032–1038

    CAS  PubMed  Google Scholar 

  12. Hampton GR, Kohen D, Bird AC (1983) Visual prognosis of disciform degeneration in myopia. Ophthalmology 90(8):923–926

    Article  CAS  PubMed  Google Scholar 

  13. Yoshida T et al (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110(7):1297–1305

    Article  PubMed  Google Scholar 

  14. Avila MP et al (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91(12):1573–1581

    Article  CAS  PubMed  Google Scholar 

  15. Hayashi K et al (2010) Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 117(8):1595–1611, 1611 e1–4

    Google Scholar 

  16. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581–611

    Article  CAS  PubMed  Google Scholar 

  17. Seko Y et al (1999) Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 40(13):3287–3291

    CAS  PubMed  Google Scholar 

  18. Laud K et al (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26(8):960–963

    Article  PubMed  Google Scholar 

  19. Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26(9):1093–1094

    Article  PubMed  Google Scholar 

  20. Yamamoto I et al (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91(2):157–160

    Article  PubMed Central  PubMed  Google Scholar 

  21. Hernandez-Rojas ML et al (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27(6):707–712

    PubMed  Google Scholar 

  22. Mandal S et al (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17(4):620–626

    CAS  PubMed  Google Scholar 

  23. Chan WM et al (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114(12):2190–2196

    Article  PubMed  Google Scholar 

  24. Rheaume MA, Sebag M (2008) Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 43(5):576–580

    Article  PubMed  Google Scholar 

  25. Rensch F et al (2008) Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 39(3):182–185

    Article  PubMed  Google Scholar 

  26. Ruiz-Moreno JM et al (2010) Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 30(10):1609–1615

    Article  PubMed  Google Scholar 

  27. Silva RM et al (2010) Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 30(3):407–412

    Article  PubMed  Google Scholar 

  28. Gharbiya M et al (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147(1):84–93 e1

    Article  CAS  PubMed  Google Scholar 

  29. Ikuno Y et al (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147(1):94–100e1

    Article  CAS  PubMed  Google Scholar 

  30. Hayashi K et al (2009) Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 148(3):396–408

    Article  CAS  PubMed  Google Scholar 

  31. Schmidt-Erfurth U et al (2005) Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 112(12):2061–2069

    Article  PubMed  Google Scholar 

  32. Jonas JB et al (2007) Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 23(3):240–242

    Article  CAS  PubMed  Google Scholar 

  33. Yenerel NM, Dinc UA, Gorgun E (2008) A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 24(3):362–363

    Article  CAS  PubMed  Google Scholar 

  34. Alkuraya HS et al (2009) Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol 29(5):411–413

    Article  PubMed  Google Scholar 

  35. Mason JO 3rd et al (2008) Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 28(4):564–567

    Article  PubMed  Google Scholar 

  36. Jalil A, Fenerty C, Charles S (2007) Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond) 21(12):1541

    Article  CAS  Google Scholar 

  37. Heiduschka P et al (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48(6):2814–2823

    Article  PubMed  Google Scholar 

  38. Ikuno Y et al (2010) Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci 51(7):3721–3725

    Article  PubMed  Google Scholar 

  39. Michels S et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112(6):1035–1047

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cathay General Hospital, Taipei City, Taiwan, ROC

    I-Chia Liang, Yu-Ying Chang, Tong-Sheng Lee, Yi-Ru Lin & Kwan-Rong Liu

  2. Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan, ROC

    Tong-Sheng Lee

  3. Taiwan Adventist Hospital, No. 424, Sec. 2, Bade Rd., Songshan Dist., Taipei City, 105, Taiwan, ROC

    Yi-Ru Lin & Kwan-Rong Liu

  4. Naional Taiwan University Hospital, Taipei City, Taiwan, ROC

    Kwan-Rong Liu

Authors
  1. I-Chia Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Ying Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tong-Sheng Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi-Ru Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kwan-Rong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kwan-Rong Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, IC., Chang, YY., Lee, TS. et al. Treatment of myopic choroidal neovascularization with posterior sub-Tenon’s bevacizumab injection (Avastin®). Int Ophthalmol 34, 971–977 (2014). https://doi.org/10.1007/s10792-014-9907-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-014-9907-y

Keywords

Search

Navigation